Working… Menu
Trial record 28 of 44 for:    Gadoxetate

MRI of the Liver With Eovist

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01215838
Recruitment Status : Terminated (Unable to meet enrollment expectations.)
First Posted : October 7, 2010
Last Update Posted : October 14, 2013
Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma
Information provided by (Responsible Party):
University of Washington

Brief Summary:
The purpose of this study is to determine if a new magnetic resonance (MR) protocol is better at diagnosing liver lesions.

Condition or disease
Hepatocellular Carcinoma

Detailed Description:

Hepatocellular carcinoma (HCC), a form of liver cancer, is the seventh most common cause of cancer mortality in the US. The incidence rate of HCC is increasing along with the incidence of Hepatitis B and C which are known to promote HCC. Patients have a better prognosis (survival outlook) if HCC is found and treated at an early stage. MRI is the best imaging modality for diagnosing HCC.

This study will compare standard MRIs and MRIs performed with a newly developed MR protocol to determine if it is possible to more confidently diagnose HCC.

Layout table for study information
Study Type : Observational
Actual Enrollment : 4 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Dynamic Contrast Evaluation of the Liver Using Gadoxetate Disodium (Eovist®) for Hepatocellular Carcinoma (HCC)
Study Start Date : August 2010
Actual Primary Completion Date : August 2011
Actual Study Completion Date : January 2012

Primary Outcome Measures :
  1. Accuracy of a new MR protocol in diagnosing HCC and other liver lesions. [ Time Frame: One day: participants will have one MRI of the liver. ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with known hepatocellular carcinoma undergoing MRI of the liver in the UWMC Radiology Clinic.

Inclusion Criteria:

  • known hepatocellular carcinoma
  • undergoing MRI of the liver

Exclusion Criteria:

  • Contraindication to MRI with IV contrast

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01215838

Sponsors and Collaborators
University of Washington
Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma
Layout table for investigator information
Principal Investigator: Orpheus Kolokythas, MD University of Washington

Layout table for additonal information
Responsible Party: University of Washington Identifier: NCT01215838     History of Changes
Other Study ID Numbers: DI-2009-1
7160 ( Other Identifier: FHCRC )
First Posted: October 7, 2010    Key Record Dates
Last Update Posted: October 14, 2013
Last Verified: October 2013
Keywords provided by University of Washington:
hepatocellular carcinoma
magnetic resonance
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases